
Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
A 60-Year Old Man With Untreated Stage IV EGFR-Mutated Non-Small Cell Lung Cancer
Case: A 60-Year-Old Male with Untreated Stage IVEGFR+NSCLC
Initial presentation
Clinical workup
Treatment




